High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-1.300
-29.71%
--
--
-1.569
-27.71%
--
--
-1.439
-25.84%
Estimates Revision
The market is revising Downward the revenue expectations for Biohaven Ltd. (BHVN) for FY2025, with the revenue forecasts being adjusted by -48.8% over the past three months. During the same period, the stock price has changed by -39.45%.
Revenue Estimates for FY2025
Revise Downward
-48.8%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-13.63%
In Past 3 Month
Stock Price
Go Down
-39.45%
In Past 3 Month
13 Analyst Rating
Wall Street analysts forecast BHVN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BHVN is 16.82 USD with a low forecast of 9.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
5 Hold
0 Sell
Moderate Buy
Current: 9.610
Low
9.00
Averages
16.82
High
30.00
Current: 9.610
Low
9.00
Averages
16.82
High
30.00
H.C. Wainwright
H.C. Wainwright
Buy
to
Neutral
downgrade
$30 -> $11
2025-12-03
New
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$30 -> $11
2025-12-03
New
downgrade
Buy
to
Neutral
Reason
H.C. Wainwright downgraded Biohaven to Neutral from Buy with a price target of $11, down from $30. The company reduced operating expenses and raised additional funding, "but now needs clear wins to keep the pipeline moving," the analyst tells investors in a research note. The firm sees a low likelihood that opakalim's Phase 3 data will exceed, or even match, azetukalner's efficacy. It downgrades the shares seeing "fewer ways to win."
UBS
Buy -> Neutral
downgrade
$26 -> $11
2025-11-26
Reason
UBS
Price Target
$26 -> $11
2025-11-26
downgrade
Buy -> Neutral
Reason
UBS downgraded Biohaven to Neutral from Buy with a price target of $11, down from $26. The firm says the company's "multiple" research and development and regulatory setbacks have lowered confidence on the viability of its remaining pipeline programs. Most of the immediate value in Biohaven's pipeline comes from Kv7, but the company is two years behind competitor Xenon in the primary indication, the analyst tells investors in a research note. UBS sees a balanced risk/reward for the shares into the upcoming pipeline catalysts.
JPMorgan
Overweight -> NULL
downgrade
$47 -> $15
2025-11-20
Reason
JPMorgan
Price Target
$47 -> $15
2025-11-20
downgrade
Overweight -> NULL
Reason
JPMorgan lowered the firm's price target on Biohaven to $15 from $47 and keeps an Overweight rating on the shares. The firm finds it "prudent" for Biohaven to undertake cost optimization efforts and restructure its business priorities following the complete response letter for Vyglxia. This should help refocus investor attention on the company's key value drivers, the analyst tells investors in a research note.
Morgan Stanley
Overweight
to
NULL
downgrade
$54 -> $26
2025-11-18
Reason
Morgan Stanley
Price Target
$54 -> $26
2025-11-18
downgrade
Overweight
to
NULL
Reason
Morgan Stanley lowered the firm's price target on Biohaven to $26 from $54 and keeps an Overweight rating on the shares. After the company received a Complete Response Letter from the FDA regarding its NDA for Troriluzole in spinocerebellar ataxia, the firm removed Troriluzole and updated its model following Q3 results. The next catalyst for the stock is Opakalim Phase 2 data in major depressive disorder that is expected in Q4, the analyst tells investor
Citi
Buy
downgrade
$28 -> $14
2025-11-13
Reason
Citi
Price Target
$28 -> $14
2025-11-13
downgrade
Buy
Reason
Citi lowered the firm's price target on Biohaven to $14 from $28 and keeps a Buy rating on the shares. The firm cites the complete response letter in spinocerebellar ataxia for the target cut. Citi remains cautious into Biohaven's upcoming Phase 3 depression data but says the recent equity raise alleviates a near-term financing overhang.
BTIG
Buy
downgrade
$33 -> $16
2025-11-06
Reason
BTIG
Price Target
$33 -> $16
2025-11-06
downgrade
Buy
Reason
BTIG lowered the firm's price target on Biohaven to $16 from $33 and keeps a Buy rating on the shares following Tuesday's announcement of the complete response letter for troriluzole in SCA. The CRL likely "ends a messy chapter" for the company in SCA, the analyst tells investors in a research note. The 60% R&D restructuring is hard to model without details, so the calculated $16 TP may be a little low pending a better read on cuts, the firm added.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Biohaven Ltd (BHVN.N) is -2.20, compared to its 5-year average forward P/E of -4.33. For a more detailed relative valuation and DCF analysis to assess Biohaven Ltd 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-4.33
Current PE
-2.20
Overvalued PE
-2.65
Undervalued PE
-6.01
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-3.49
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.70
Undervalued EV/EBITDA
-6.28
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
65622.30
Current PS
0.00
Overvalued PS
292719.92
Undervalued PS
-161475.33
Financials
Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
Trading Trends
Insider
Insiders areBuying! The selling amount has increased 3226.99% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areBuying! The selling amount has increased 3226.99% over the last month.
Sold
Bought
BHVN News & Events
Events Timeline
(ET)
2025-11-12
08:05:12
Biohaven Prices 23.33M Share Spot Secondary Offering at $7.50
2025-11-11 (ET)
2025-11-11
16:20:17
Biohaven Launches $150M Spot Secondary Offering; Price Set Between $7.50 and $8.00
2025-11-11
16:08:22
Biohaven reveals $150M common stock offering
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/104a7c36c1f7b464ffd6c8fc8c3580323adf2407558afc5a35381c4d18a0fdbc.png)
Preview
4.0
12-03BenzingaWayfair Analyst Changes Stance; Check Out Wednesday's Top 5 Downgrades
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/eee6201e90902fa3c6bf0ec27e54487df55740af28a09ef4f7d98a2691667b3f.png)
Preview
6.0
11-26BenzingaUBS Adjusts Biohaven Rating to Neutral and Reduces Price Target to $11
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/9a7d2d7a307da4aba7e2704a51b236c777527a7bd32adc7794a6b90bd82f5b05.png)
Preview
4.0
11-21BenzingaJP Morgan Keeps Overweight Rating on Biohaven, Reduces Price Target to $15
Sign Up For More News
People Also Watch
FAQ
What is Biohaven Ltd (BHVN) stock price today?
What is Biohaven Ltd (BHVN)'s business?
What is the price predicton of BHVN Stock?
What is Biohaven Ltd (BHVN)'s revenue for the last quarter?
What is Biohaven Ltd (BHVN)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Biohaven Ltd (BHVN)'s fundamentals?
How many employees does Biohaven Ltd (BHVN). have?